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Abstract: Abnormalities in melatonin physiology may be involved or closely linked to the 
pathophysiology and behavioral expression of autistic disorder, given its role in 
neurodevelopment and reports of sleep-wake rhythm disturbances, decreased nocturnal 
melatonin production, and beneficial therapeutic effects of melatonin in individuals with 
autism. In addition, melatonin, as a pineal gland hormone produced from serotonin, is of 
special interest in autistic disorder given reported alterations in central and peripheral 
serotonin neurobiology. More specifically, the role of melatonin in the ontogenetic 
establishment of circadian rhythms and the synchronization of peripheral oscillators opens 
interesting perspectives to ascertain better the mechanisms underlying the significant 
relationship found between lower nocturnal melatonin excretion and increased severity of 
autistic social communication impairments, especially for verbal communication and social 
imitative play. In this article, first we review the studies on melatonin levels and the 
treatment studies of melatonin in autistic disorder. Then, we discuss the relationships 
between melatonin and autistic behavioral impairments with regard to social communication 
(verbal and non-verbal communication, social interaction), and repetitive behaviors  
or interests with difficulties adapting to change. In conclusion, we emphasize that  
randomized clinical trials in autism spectrum disorders are warranted to establish potential 
therapeutic efficacy of melatonin for social communication impairments and stereotyped 
behaviors or interests. 
Keywords: melatonin; biological clocks; circadian rhythm; synchrony; autism spectrum 
disorders; social communication; stereotyped behaviors 
 
1. Introduction 
Melatonin is a neurohormone well known for its effect on the regulation of the circadian sleep-wake 
rhythm. In physiologic conditions, its plasmatic concentration follows a circadian rhythm, with low 
levels during the day and high levels at night; in humans, the peak secretion is typically occurring at 
around 2 AM and melatonin has been called the darkness hormone [1]. 
Since its discovery [2], the biosynthesis and molecular action of melatonin 
(5-methoxy-N-acetyltryptamine) have been thoroughly studied. Melatonin is mainly synthesized by the 
pinealocytes in the pineal gland [3]. This synthesis is entrained by ambient light under the control of the 
circadian clock located in the suprachiasmaic nuclei (SCN) of the hypothalamus [4]. Melatonin is 
produced from the amino acid tryptophan which hydroxylated and then decarboxylated to form 
5-hydroxytryptamine or serotonin. Serotonin is first acetylated through the action of the (typically) 
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rate-limiting arylalkylamine-N-acetyltransferase (AA-NAT, also termed “Timezyme”), and then 
O-methylated by acetylserotonin O-methyltransferase (ASMT) to yield melatonin [5]. Both AA-NAT 
and ASMT activities are controlled by noradrenergic and neuropeptidergic projections to the pineal 
gland [6]. Once synthesized, melatonin is immediately released into the systemic circulation to reach 
peripheral and central target tissues. At this level, the melatonin distributes a nocturnal/circadian 
message within the entire body to regulate daily and seasonal physiological rhythms through three 
different molecular pathways. The most well characterized pathway is the binding and activation of the 
membrane specific G protein-coupled melatonin receptors MT1 andMT2 as well binding to the MT3 site 
shown to be the enzyme quinone reductase 2) [7]. It appears that melatonin also interacts with nuclear 
receptor and intracellular proteins [8]. In the liver, melatonin is rapidly metabolized to 6-hydroxymelatonin 
by the action of the cytochrome P450 enzyme CYP1A2, leading to a short half-life in the circulation  
(20 to 40 min). Plasma levels can be directly measured or indirectly assessed through salivary measures. 
Production of melatonin over time can be assessed via measurement of its inactive urinary metabolite, 
6-sulphatoxymelatonin (sulfated 6-hydroxymelatonin).  
The crucial role of melatonin as a modulator of sleep is well documented. First, disturbances in 
melatonin levels have been documented with regard to circadian rhythm sleep disorders [1]. Second, 
administration of exogenous melatonin has been reported to improve sleep-wake rhythm disturbances 
and to affect sleep latency [9–11]. In a recent experimental study, authors demonstrated that, depending 
on the activated melatonin receptors (MT1, MT2 or both) melatonin regulates differently the vigilance 
states: MT2 receptors are mainly involved in non-rapid eye movement sleep, whereas MT(1) receptors 
are mainly involved in rapid eye movement sleep [12]. In addition to its influence on the daily 
sleep-wake cycle, melatonin has a large spectrum of effects [13]. At an experimental level, melatonin 
has been shown to influence basal metabolism, oxidative stress, inflammation, apoptosis [14–18] and to 
prevent premature aging and tumorigenesis [19]. Interestingly, in humans and animals, melatonin seems 
to have also an influence on cognitive functions. In mice models of Down syndrome (Ts65Dn mice), 
melatonin reduces neurodegenerative processes and improves cognitive abilities [20]. In rats with 
epilepsy, melatonin treatment improved deficits in hippocampus-dependent working memory and 
behavioral alterations associated with hyperactivity [21]. Finally, melatonin has been reported to 
significantly improve cognitive abilities and mood in patients with mild cognitive impairment [22]. 
The effect of exogenously administered melatonin on the circadian clock (chronobiotic properties) 
and circadian activity rhythms has been documented [23–25]. More recently, its role as a neuroendocrine 
synchronizer of molecular oscillatory systems has been studied [26,27]. The results provide evidence 
that melatonin plays a major role in the circadian oscillatory rhythms observed in the expression of 
several clock genes, such as PER1, PER2, BMAL1, REV-ERBα, CLOCK and CRY1, in both central and 
peripheral melatonin target tissues. Indeed, in animal models, PER1 expression is undetectable in 
melatonin-deficient mice [28,29] and pinealectomy abolishes rhythmic expression of PER1 in the Pars 
tuberalis (PT) [30] and results in desynchronized PER1 and PER2 expressions in the SCN [31]. 
Moreover, it was recently reported that the mutation of PER1 in mice significantly altered the rhythms of 
cytokine and cytolytic factors in splenic natural killer (NK) cells resulting in altered rhythms of NK 
cellular clocks and immune pathways [32]. Melatonin synchronizes circadian oscillations in the 
cardiovascular system by influencing circadian rhythmic expression of both PER1 and BMAL1 in the rat 
heart [33]. In adipose tissue, melatonin synchronizes metabolic and hormonal function [34] by 
Int. J. Mol. Sci. 2013, 14 20511 
 
regulating PER2, CLOCK and the nuclear receptor REV-ERBα [35]. The latter is essential for the daily 
balance of carbohydrate and lipid metabolism [36]. Finally, melatonin regulates oscillation of CLOCK 
genes in healthy and cancerous human breast epithelial cells [37], induces a shift in the 24-h oscillatory 
expression of PER2 and BMAL1 in cultured fetal adrenal gland [38] and influences rhythmic circadian 
modulation protein synthesis in hepatocytes [39] and erythrocytes [40]. 
Taken together, these studies underline the major role of melatonin in the regulation of human 
circadian rhythms including the sleep-wake, neuroendocrine and body temperature cycles [41,42], and 
more specifically in the synchronization of peripheral oscillators (i.e., in the adjustment of the timing of 
existing oscillations). Measures of melatonin are considered the best peripheral indices of human 
circadian timing [43]. 
Finally, there is increasing evidence that melatonin is critically involved in early development 
through its direct effects on placenta, developing neurons and glia, and its role in the ontogenetic 
establishment of diurnal rhythms [44,45]. This strengthens interest in the study of melatonin in 
developmental disorders, in particular when these developmental disorders are associated with 
alterations in the sleep-wake cycle. Autistic disorder—a pervasive developmental disorder characterized 
by communication and social interaction impairments associated with repetitive interests and 
behaviors—provides an interesting and challenging model of abnormal melatonin production in early 
developmental disorders and its possible relationships with autistic behavioral impairments. This model 
offers promising avenues, developed in the next sections, for potential therapeutic benefits of melatonin 
and a better understanding of its role in social communication development, as a synchronizer and 
regulator of the circadian rhythms network.  
2. Melatonin in Autism 
Melatonin is of interest in autism spectrum disorder (ASD) due to its apparent role in 
neurodevelopment [46] and reports of sleep-wake rhythm disturbances in individuals with autism [47]. 
More specifically, reduced total sleep and longer sleep latency as well as nocturnal and early morning 
awakenings, are often reported for individuals with ASD [48–55]. In addition, central and peripheral 
alterations in serotonin in autism have been widely reported and, as mentioned, melatonin is synthesized 
in only two steps from serotonin in the pineal gland and the gut. [53,56,57].  
Prior studies of melatonin production in autistic disorder were often limited by small sample sizes and 
were not entirely consistent, but all reported abnormalities in the melatonin production (see Table 1). 
Our results [58,59], taken together with the other studies, strongly indicate that nocturnal secretion of 
melatonin is often low in autism. It is noteworthy that melatonin abnormalities have been found in 
several other disorders with intellectual disability [60,61], raising the issue of the non-specificity of the 
melatonin findings in ASD. However, melatonin production in Down syndrome has been reported to be 
normal, while increased levels have been reported for Fragile X individuals [62,63]. 
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Table 1. Studies of melatonin in individuals with autism. 
Study Sample Study group Measured variable Results 
Ritvo et al. (1993) 
[64] 
Urine Young adults with autism (n = 10) Melatonin concentration 
Increased daytime values compared to typically  
developing controls; 
Similar nighttime values compared to typically  
developing controls 
Nir et al. (1995) [65] Serum Young men with autism (n = 10) Melatonin concentration 
Increased daytime values compared to typically  
developing controls; 
Decreased nighttime values compared to typically  
developing controls 
Kulman et al. (2000) 
[66] 
Serum Children with autism (n = 14) 
Melatonin concentration 
(24-h circadian rhythm) 
Decreased nighttime values compared to typically developing 
controls; 
No circadian variation in 10/14 (71.4%) children with autism; 
Inverted rhythm in 4/14 (28.6%) children with autism 
Tordjman et al. 
(2005) [58] 
Urine 
Children and adolescents with 
autism (n = 49) 
6-Sulphatoxymelatonin 
excretion rate  
(12-h collection) 
Decreased nighttime values compared to typically  
developing controls; 
Melke et al. (2008) 
[67] 
Plasma 
Adolescents and young adults with 
autism (n = 43) 
Melatonin concentration  
Decreased daytime values compared to typically  
developing controls 
Mulder et al. (2010) 
[68] 
Urine 
Children and adolescents with 
autism (n = 20) 
6-Sulphatoxymelatonin 
excretion rate  
(24-h collection) 
Trend to lower 24-h melatonin excretion rate in 
hyperserotonemic compared to normoserotonemic individuals 
with autism 
Tordjman et al. 
(2012) [59] 
Urine 
Postpubertal adolescents and 
young adults with autism (n = 43) 
6-Sulphatoxymelatonin 
nexcretion rate  
(split 24-h collection)  
Decreased daytime values compared to typically  
developing controls; 
Decreased nighttime values compared to typically  
developing controls 
No circadian variation in 10/43 (23.2%) individuals with autism  
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Furthermore, nocturnal excretion of 6-SM was significantly negatively correlated with severity of 
autistic impairments in verbal communication and play [58,59]. In addition, our study [58] conducted on 
43 individuals with autism, showed low daytime excretion of melatonin in autism that is consistent with 
Melke et al.’s study [67], but contrasts with previous smaller studies of urinary melatonin [64] and  
serum melatonin [65] reporting higher daytime levels in autism. Our findings [59] taken together with 
Melke et al.’s findings [67] demonstrate that there is a deficit in melatonin production in a substantial 
proportion of individuals with autism and this deficit is present at night and during the day, indicating 
that pineal and, possibly, extra-pineal production of melatonin is lower in autism. A potential 
contribution of the ASMT enzyme to the observed reduced melatonin production in ASD has been 
considered given that several of the identified mutations of the ASMT gene reduce or abolish ASMT 
activity (the allelic frequency of ASMT deleterious mutations ranges from 0.66% in Europe to 2.97% in 
Asia) [69]. Melke et al. [67] identified mutations and Cai et al. [70] identified microduplications in 
ASMT, possibly leading to a decrease in ASMT activity in individuals with ASD. However, the ASMT 
findings of Melke et al. have not been replicated and ASMT mutations have been also found in healthy 
individuals [71,72]. In addition, mutations altering the functional properties of melatonin receptors have 
been found in individuals with ASD. Although mutations in MT1 and MT2 receptors do not represent 
major risk factors for ASD [73], they should also be examined as potential contributors to altered 
melatonin physiology in ASD. Finally, environmental factors occurring at a critical period of 
development and interacting with genetic factors might contribute to low melatonin levels in ASD. 
Thus, summer birth was found to be a risk factor for autism according to the 2011 Gardener et al. [74] 
meta-analysis conducted on 64 studies (summer birth was significantly associated with an elevated risk 
of autism, RR = 1.14, p = 0.02). Given that the summer season corresponds to the longest days of  
the year, a possible role of an early deficit in melatonin in the development of ASD could be speculated 
(the production of melatonin is powerfully suppressed by light acting through the retino-hypothalamic 
tract [75]).  
Our result of smaller intra-individual 6-SM nighttime-daytime differences and the absence of 
melatonin variation found in some individuals with autism [59] might be a reflection of the lower day 
and nighttime levels, but might also indicate that there exists a subgroup of individuals with autism that 
have a dysregulation of their circadian rhythm, and more precisely an absent circadian rhythm. The 
hypothesis of an absent circadian rhythm in melatonin and other neuroendocrine functions is supported 
by Kulman et al.’s study [66] in which 10 out of 14 children with autistic disorder showed no melatonin 
circadian variation (see Table 1), by Zapella [76] who found a blunted circadian rhythm of melatonin 
secretion in a male adolescent with autism and hypomelanosis of Ito, and by several reports in autism of 
abnormalities in the circadian rhythm of cortisol secretion including an attenuated circadian variation 
(see the Tordjman et al. review [77]). The possible existence and characteristics of a subgroup of patients 
with autism showing a deficit in melatonin production with no nighttime-daytime variations may be 
fruitfully examined in future larger studies.  
Finally, beneficial effects of melatonin when administered to individuals with autism and sleep 
problems have been reported and strengthen the interest to study melatonin in autism [78–80]. These 
studies are reviewed in the next section. 
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Table 2. Studies on potential therapeutic benefits of melatonin in autistic disorder. 
Study Journal Population Design 
Duration of 
treatment 
Melatonin 
(formulation, 
dose) 
Time of 
intake  
Main outcome 
measures 
Effects on sleep Other outcomes Comments 
Single case reports 
Horrigan and 
Barnhill, 1997 
[81] 
J. Am. 
Academy 
Child and 
Adolesc. 
Psychiatry 
17 year old boy with Asperger's 
Syndrome (AS) 
_____ Not Given 3 mg 
20–30 
min 
before 
bedtime 
(BB) 
Sleep 
Sleep 
improvement.  
No side effects 
Daytime behavior improvement _____ 
Hayashi, 2000 
[82] 
Psychiatry 
Clin. 
Neurosc. 
14-year-old boy with autistic 
disorder, severe intellectual 
disability and phase delay with 
polyphasic sleep 
_____ 4 months 
Immediate 
Release  
(IR) 6 mg 
11:00 
PM 
Sleep 
Melatonin 
increased sleep 
duration. No side 
effects 
None _____ 
Jan et al., 2004 
[83] 
Dev. 
Med.Child 
Neurol. 
12 year-old boy with AS and 
complex sleep disturbance 
(phase delay and parasomnias) 
_____ 6 months 
Controlled 
Release (CR) 
5 mg 
30 min 
BB 
Sleep 
Normalization of 
the sleep-wake 
rhythm and 
disappearance of 
parasomnias. No 
side effects 
None _____ 
Retrospective studies 
Gupta and 
Hutchins, 2005 
[84] 
Arch. Dis. 
Child 
9 cases of children with Autistic 
Disorder (AD) aged from 2–11 
years. Chronic sleep problems 
Not Given 
1 week  
to 1 year 
IR 2.5–5 mg 
45 min 
BB 
Parental evaluation 
of sleep 
56% showed 
improvement in 
total sleep 
duration  
None 
No 
standardized 
collection of 
sleep 
variables 
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Table 2. Cont. 
Study Journal Population Design 
Duration of 
treatment 
Melatonin 
(formulation, 
dose) 
Time of 
intake  
Main outcome 
measures 
Effects on sleep Other outcomes Comments 
Andersen  
et al., 2008 [85] 
J. Child. 
Neurol. 
107 children and adolescents 
aged from 2–18 years with ASD 
(DSM-IV): 71% AD, 5% AS, 
19% PDDNOS (Pervasive 
Developmental Disorder Not 
Otherwise Specified) 
Not Given 
Mean 
Duration:  
1.8 years 
IR in 91% of 
the cases. 
Dose 
escalation 
protocol from 
1 to 6 mg 
based upon 
age 
30–60 
min BB 
Parental evaluation 
of sleep 
Parents reported 
full (25%) or 
partial (60%) 
improvement. 
Beneficial effects 
of melatonin seem 
to stop after 3 to 12 
months despite the 
use of higher 
doses. Side effects 
observed in 3 
children: 
sleepiness, 
fogginess, 
increased enuresis 
None 
No 
standardized 
collection of 
sleep 
variables. The 
loss of 
response to 
melatonin 
treatment is 
discussed in 
the text 
Galli-Carminatti 
et al., 2009 [86] 
Swiss. Med. 
Wkly 
6 adult patients  
with AD (CIM-10) and 
intellectual disability,  
aged from 19–52 years 
Not Given 6 months 
IR. Dose 
escalation 
protocol from 
3 to 9 mg if 
clinically 
required 
45 min 
BB 
Sleep  
(CGI-S and CGI-I)  
Improvement in 
sleep onset 
latency, night and 
early morning 
awakenings. No 
side effects 
None 
 No 
standardized 
collection of 
sleep 
variables.  
2 to 4 
associated 
psychotropic 
drugs per 
patient 
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Table 2. Cont. 
Study Journal Population Design 
Duration of 
treatment 
Melatonin 
(formulation, 
dose) 
Time 
of 
intake  
Main outcome 
measures 
Effects on sleep Other outcomes Comments 
Open label trials 
Jan et al., 
1994 [87] 
Dev. Med. Child 
Neurol. 
15 children with multiple 
neurological disabilities and 
severe sleep disorders 
Not Given Not Given 2–10 mg 
bedtim
e 
Not Given 
Partial improvement in 
sleep disorders. No side 
effects 
Behavior and social 
improvement 
Heterogeneou
s sleep 
disorders and 
neurological 
disabilities 
Ishizaki  
et al., 1999 
[88] 
No To Hattatsu 
50 children and young adults 
with autism (n = 27) or 
mentally retardation (n = 20) or 
severe motor/intellectual 
disability (n = 3) aged from 
3–28 years with sleep disorders 
Not Given Not Given Not Given 
Not 
Gven 
Sleep disorders 
and 
emotional/behavi
or disturbances  
34 patients experienced 
improvement in response to 
melatonin. Side effects 
reported in 17 patients 
Improvements in excitability 
when sleep also improved. No 
change in contrariness, 
stereotyped behavior and in 
school/workshop refusal 
Various types 
of insomnia 
and diagnoses 
Paavonen  
et al., 2003 
[89] 
J. Child. Adolesc. 
Psychopharmacol
. 
15 children with AS (DSM-IV) 
aged from 6–17 years with 
severe sleep problems for at 
least 3 months  
Not Given 14 days IR 3 mg 
30 min 
BB 
Sleep 
(72h-period 
actigraphy, sleep 
diaries), daytime 
behavior 
(Karolina 
Sleepiness Scale: 
KSS), Child 
Behavior Check 
List (CBCL) 
Melatonin treatment was 
associated with significant 
decrease in sleep onset 
latency and nocturnal 
activity. Discontinuation of 
melatonin led to a 
significant decrease in 
sleep duration and more 
nocturnal activity. Side 
effects in 20% of the cases: 
tiredness, headaches, 
severe sleepiness, 
dizziness, diarrhoea 
Significant improvement of 
daytime behavior (CBCL) 
No principal 
outcome 
specified. KSS 
is not 
validated in 
children nor in 
ASD  
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Table 2. Cont. 
Study Journal Population Design 
Duration of 
treatment 
Melatonin 
(formulation, 
dose) 
Time 
of 
intake  
Main outcome 
measures 
Effects on sleep Other outcomes Comments 
Giannotti  
et al., 2006 
[90] 
J Autism 
Dev. 
Disord. 
29 children with AD (DSM-IV) 
aged from 2–9 years with 
current sleep problems 
Controlled-release 
melatonin 
6 months 
Dose 
escalation 
protocol from 
3 mg (1 mg of 
IR+2mg of 
CR) to 6 mg 
when 
clinically 
required, 
based upon 
age (max 4 
mg under 4 
years old and 
max 6mg 
over  
6 years old) 
08:00 
PM 
Sleep (diaries 
and Children 
Sleep Habits 
Questionnaire 
CSHQ), daytime 
behavior, 
Children Autistic 
Rating Scale 
(CARS) 
Melatonin treatment was 
associated with improvement 
in sleep onset latency, night 
awakenings and sleep 
duration which vanished after 
melatonin discontinuation. 
No side effects 
Parents reported less 
irritability, less 
anxiety and better 
mood. Significant 
improvement of 
depression, anxiety 
and withdrawal 
symptoms during 
melatonin treatment 
in children with AS. 
No effect was 
reported on the 
CARS 
No principal outcome 
specified. Missing 
data: analyses on  
25 patients 
De 
Leersnyder 
et al., 2011 
[91] 
Pediatr. 
Neurolog. 
88 children with heterogeneous 
neurodevelopmental disorders 
(Smith Magenis syndrome, 
mental retardation, 
encephalopathy, Angelman 
syndrome, Rett syndrome, 
Bourneville syndrome, 
blindness and autism) aged 
5–20 years. 7 patients with 
autism, mean age 12 years old 
6 years of open 
label follow up 
3 months 
CR 2–4 mg 
(<40 kg) or  
6 mg (>40 
kg) based 
upon weight  
60 min 
BB 
Parental 
evaluation of 
sleep and mood 
(self-constructed 
questionnaire) 
According to parental reports, 
both sleep latency and sleep 
duration improved within 3 
months such as night 
awakenings, sleep quality and 
daytime napping. 11 children 
experienced adverse events 
(daytime nap, difficulties in 
swallowing tablets) that the 
parents attributed to 
melatonin treatment 
12% of the parents 
reported 
improvements of 
mood in their 
children  
Heterogeneous 
neurodevelopmental 
disorders. Results can't 
apply to a population 
with autism spectrum 
disorders. No 
standardized collection 
of sleep and mood 
parameters. Mean dose 
for patients with 
autism: 5.7 mg 
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Table 2. Cont. 
Study Journal Population Design 
Duration of 
treatment 
Melatonin 
(formulation, 
dose) 
Time of 
intake  
Main outcome 
measures 
Effects on sleep Other outcomes Comments 
Malow  
et al., 2011 
[92] 
J. Autism 
Dev. 
Disord. 
24 children with ASD 
(DSM-IV, ADOS): AD, AS 
and PDDNOS aged from 3–9 
years. Sleep onset delay of 30 
min or longer confirmed on 
actigraphy. Exclusion of 
neurodevelopmental 
disabilities such as fragile X, 
Down and Rett syndromes 
 Before 
treatment 
families 
received 
structured 
sleep 
education and 
children 
underwent a 
treatment 
acclimatation 
phase in order 
to be sure the 
melatonin 
will be taken 
14 weeks 
CR. Dose 
escalation 
protocol from 
2–9 mg when 
clinically 
required 
30 min 
BB 
Sleep (actigraphy, 
Children Sleep 
Habits 
Questionnaire 
CSHQ, diaries), 
daytime behavior 
(Child Behavior 
Check List 
CBCL, Repetitive 
Behavior 
Scale-Revisited), 
parental stress 
(Parenting Stress 
Index Short 
Form), side 
effects (Hague 
Side Effects 
Scale) 
Significant improvement in 
sleep latency within the first 
week of treatment but not for 
other sleep parameters such as 
night awakenings and sleep 
quality 
Significant improvement 
in children behavior 
(withdrawal, affective 
problems, 
attention-deficit 
hyperactivity, 
stereotyped and 
compulsive behaviors). 
Significant improvement 
in parental stress 
No placebo 
Placebo-controlled trial 
McArthur 
and 
Budden, 
1998 [93] 
Dev. Med. 
Child 
Neurol. 
9 children and adolescents 
with Rett syndrome aged 
from 4 to 17 years. Mean age 
:10 years old 
Randomised 
double-blind 
crossover 
trial 
2 periods of  
4 weeks with 
a wash out 
period of  
1 week 
2.5–7.5 mg 
based on 
weight 
60 min 
BB 
Sleep (actigraphy, 
diaries) 
Significant improvement in total 
sleep time. No side effects. 
None _____ 
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Table 2. Cont. 
Study Journal Population Design 
Duration of 
treatment 
Melatonin 
(formulation, 
dose) 
Time of 
intake  
Main outcome 
measures 
Effects on sleep Other outcomes Comments 
Garstang 
and 
Wallis, 
2006 [94] 
Child Care 
Health 
Dev. 
11 children and adolescents 
with ASD aged from 5–15 
years with chronic sleep 
disorders resistant to 
behavioral treatment 
Randomised 
double-blind 
crossover 
trial 
2 periods of  
4 weeks with a 
wash out period 
of 1 week 
 IR 5 mg 
60 min 
BB 
Sleep (diary) 
Melatonin and placebo were 
associated with significantly 
decreased sleep latency and 
nocturnal awakenings, 
increased total sleep time. No 
side effects 
Several parents 
and class 
teachers 
commented that 
their children 
were easier to 
manage and less 
rigid in their 
behavior while 
taking melatonin 
ASD criteria were not 
consensual. Only 7 
children completed  
the trial. Investigators 
found that some of the 
placebo capsules were 
empty. Missing data 
Wasdell  
et al., 
2008 [95] 
J. Pineal 
Res. 
51 children and adolescents 
with neurodevelopmental 
disabilities (16 patients with 
ASD) from 2–18 years. 
Sleep delay phase syndrome 
and impaired sleep 
maintenance with resistant 
to sleep hygiene intervention 
Randomised 
double-blind 
crossover 
trial. 
3-weeks 
trial 
followed by 
a 3-month 
open-label 
study. 
Bahavioral 
sleep 
treatment 
before 
inclusion 
2 periods of  
10 days with a 
wash out period 
of 3–5 days 
Dose escalation 
protocol based 
on unspecified 
conditions: from 
5 mg  
(1 mg FR +  
4 mg CR) to  
15 mg 
20–30 
min BB 
Sleep (actigraphy, 
diaries, CGI-S, 
CGI-I), familial 
stress (Family 
Stress Scale) 
Significant improvement in 
total sleep duration and sleep 
latency as well as reduced 
stress levels in parents in the 
melatonin arm 
Half of the 
patients with 
ASD had their 
dose increased 
during the 
open-label phase 
with no 
additional 
improvement in 
sleep latency or 
sleep duration, 
but caregivers 
reported less 
anxiety 
Unspecified ASD 
criteria. 50 patients 
completed the trial and 
47 completed the 
open-label phase. 
Selection bias due to 
previous melatonin 
treatment (25% of the 
cases). At the end of 
the trial, 29 patients 
received a dose of 10 
or 15 mg. Higher 
doses were necessary 
in patients with 
bilateral cerebral 
lesions 
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Table 2. Cont. 
Study Journal Population Design 
Duration of 
treatment 
Melatonin 
(formulation, 
dose) 
Time of 
intake  
Main outcome 
measures 
Effects on sleep 
Other 
outcomes 
Comments 
Wirojanan et 
al., 2009 [96] 
J. Clin. Sleep 
Med. 
12 children and 
adolescents with 
unspecified sleep 
problems, aged from 2–15 
years: 5 patients with AD 
(ADOS and ADI-R), 3 
patients with fragile X 
syndrome with AD, 3 
patients with AD and 
fragile X syndrome, and  
1 patient with fragile  
X premutation  
Randomized 
double-blind 
crossover 
trial 
2 periods of  
2 weeks. No 
wash out period 
 IR 3 mg 
30 min 
BB 
Sleep (actigraphy, 
diary) 
Significant, but mild 
improvement in total 
sleep time (+21min) and 
decrease in sleep latency 
(-28min) 
None 
Missing data: only  
12 patients completed 
the trial (order bias). No 
sub-group analysis in 
AD patients. No side 
effects 
Wright  
et al., 2011 
[97] 
J. Autism 
Dev. Disord. 
22 children and 
adolescents from 3–16 
years with ASD (ICD-10, 
ADOS, ADI-R): AD 
(70%), AS (10%) and AA 
(20%). No fragile X or 
Rett syndrome. Current 
sleeplessness (confirmed 
on a 1 month-diary) and 
resistant to behavioral 
treatment. 
Randomized 
double-blind 
crossover 
trial 
2 periods of  
3 months 
separated by  
1 month of 
washout 
 IR. Dose 
escalation 
protocol from  
2 mg to 10 mg 
when clinically 
required 
30–40 
min BB 
Sleep (Sleep 
Difficulties 
Questionnaire, 
diary), daytime 
behavior 
(Developmental 
Behavior Checklist), 
Side Effect 
Questionnaire 
Significant improvement 
in sleep latency (-47min) 
and total sleep duration 
(+52min) in the 
melatonin arm. No 
improvement in night 
awakenings. The side 
effect profile was not 
significantly different 
between the 2 groups 
 Improvement 
in children 
behavior in the 
melatonin arm 
that was 
significant for 
communication 
(p = 0.045) 
Missing data. Analysis 
on  
16 patients. No 
actigraphy. Mean 
melatonin dose: 7 mg 
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Table 2. Cont. 
Study Journal Population Design 
Duration of 
treatment 
Melatonin 
(formulation, 
dose) 
Time of 
intake  
Main outcome 
measures 
Effects on sleep Other outcomes Comments 
Cortesi  
et al., 2012 
[98] 
J. Sleep Res. 
160 children with ASD 
(DSM-IV, ADI-R, ADOS) 
aged 4–10 years with sleep 
onset insomnia and 
impaired sleep 
maintenance  
Randomized 
placebo- 
controlled. 
Randomizatio
n in 4 groups: 
1) melatonin 
alone 2) 
melatonin+ 
Cognitive 
Behavioral 
Therapy 
(CBT) 3) 
CBT alone 4) 
placebo 
12 weeks  CR 3 mg 09:00 PM 
Sleep (actigraphy, 
Children Sleep 
Habits 
Questionnaire, 
diaries) 
144 patients completed the trial and 134 
were analysed. Combination group 
showed greater significant 
improvements on sleep followed by the 
melatonin alone and the CBT alone 
compared to placebo group. No side 
effects 
None _____ 
Gringras  
et al., 2012 
[99] 
BMJ 
146 children from 3 to 15 
years with 
neurodevelopmental 
disorders (60 patients with 
ASD) and severe sleep 
disorders that did not 
respond to standardised 
sleep advice 
Double-blind 
randomised 
multicentre 
placebo- 
controlled 
phase III trial 
12 weeks 
immediate 
release 
melatonin (dose 
escalation 
protocol from 
0.5 mg to  
12 mg) or 
matching 
placebo 
45 min 
before 
bedtime 
total sleep time 
after 12 weeks 
(sleep diaries and 
actigraphy); sleep 
onset latency; 
child behavior 
(aberrant 
behavior 
checklist); family 
functioning; 
adverse events 
Melatonin increased total sleep time by 
22.4 min (diaries) and 13.3 
(actigraphy); reduced sleep onset 
latency by 37.5 min (diaries) and 45.3 
(actigraphy). Children in the melatonin 
group woke up earlier than the children 
in the placebo group. Melatonin was 
most effective in children with longest 
sleep latency. Adverse events were 
similar between the 2 groups 
Child behavior and 
family functioning 
outcomes showed 
some (but not 
significant) 
improvement and 
favoured use of 
melatonin  
The results 
are not 
specified by 
category of 
developme
ntal 
disorder 
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Table 3. Review, meta-analysis and discussion of therapeutic uses of melatonin in autistic disorder. 
Review/meta-analysis 
Jan and 
O'Donnell, 
1996 [100] 
J. Pineal Res. 
Review based on100 individuals with chronic sleep disorders, aged from 3 months to 21 years. Half of these 100 patients presented visual impairment or blindness. Melatonin dose ranged from 
2.5 to 10 mg. Higher doses were needed in patients with impaired sleep maintenance. Partial or total improvement in sleep parameters was found in 82% of the cases. No side effects  
Jan et al., 1999 
[101] 
Dev. Med. 
Child Neurol. 
Systematic review of studies on melatonin in children. 24 studies found, most of them were case reports or uncontrolled studies with small samples. Mean age: 10 years old. Associated 
diagnosis: blindness and neurodevelopmental disabilities, 1 single case of an adolescent with AS [76]. Doses ranged from 0.5 to 20 mg. Improvement in sleep in all the studies 
Phillips and 
Appleton, 2004 
[102] 
Dev. Med. 
Child Neurol. 
Only three studies, reporting a total of 35 children, fulfilled the criteria for inclusion (randomized controlled clinical trials). Two of them reported a significant decrease in time to sleep onset 
Braam et al., 
2009 [103] 
Dev. Med. 
Child Neurol. 
Meta-analysis of placebo-controlled randomized trials of melatonin in individuals with intellectual disabilities and sleep problems. 9 studies were included. Various doses and formulations of 
melatonin were given. Melatonin decreased sleep latency by a mean of 34 min (p < 0.001), significantly decreased mean number of wakes per night (p=0.024), and increased total sleep time 
by 50 min (p < 0.001). Specified reports on adverse effects were given in four studies. Adverse effects were minor and their incidence in both melatonin and placebo phases were the same. 
Patient groups in studies included in this meta-analysis were very heterogeneous 
Guénolé et al., 
2011 [79] 
Sleep Med. 
Rev. 
Systematic review of efficacy and safety of exogenous melatonin for treating disordered sleep in individuals with autism spectrum disorders: 4 case reports, 3 retrospective studies, 2 
open-label clinical trials, 3 placebo controlled trials. All studies supported the existence of a beneficial effect of melatonin on sleep in individuals with ASD with minor side effects. Limitations 
are: small sample, clinical heterogeneity of ASD and sleep disorders, varying methods used to measure sleep, confounding factors such as behavioral interventions and cross over design (no 
analysis of intention to treat). Melatonin doses ranged from 0.75 to 10 mg per day. The authors propose that future research on the efficacy of melatonin in children with ASD should include 
daytime functioning as a principal outcome measure. Only 6 patients on 205 presented side effects: daytime sleepiness, fogginess, dizziness, nocturnal enuresis, tiredness, headache, diarrhoea 
Doyen et al., 
2011 [78] 
Eur. Child 
Adolesc. 
Psychiatry 
Systematic review on pharmacokinetics data on melatonin and its role in sleep disorders and autism spectrum disorders. Authors reviewed 17 studies on effectiveness and side effects of 
melatonin in patients with AD, AS, PDD-NOS and Rett syndrome. Effectiveness on sleep disorders was found in all the studies, side effects were reported in 5 studies. Melatonin doses ranged 
from 0.5 to 10 mg. Melatonin seems to have anxiolytic properties. Most frequent reported side effects: infections, flu, epilepsy, intestinal disorders and agitation 
Rossignol and 
Frye, 2011 [80] 
Dev. Med. 
Child. 
Neurol. 
Aim of the study: investigate melatonin-related findings in ASD including AD, AS, Rett syndrome and PDDNOS. 18 studies on melatonin treatment on ASD patients were identified (5 RCT), 
12 of them reported improvement in sleep with melatonin in 67% to 100% of the patients. 6 studies reported improvement in daytime behavior (less behavioral rigidity, ease of management for 
parents and teachers, better social interaction, fewer temper tantrums, less irritability, more playfulness, better academic performance and increased alertness). Melatonin doses ranged from 
0.75 to 15 mg, age of patients ranged from 2 to 18 years, treatment duration ranged from 2 weeks to 4 years. 12 studies explored side effects (headache, tiredness, dizziness, diarrhea) in which 
7 studies reported no side effects. 9 studies found low levels or abnormal circadian rhythm of melatonin in ASD. A correlation between this abnormal levels and autistic behaviors was found 
in 4 studies. Night time urinary excretion of melatonin metabolite (6-SM) was reported to be inversely correlated with the severity of impairments in verbal communication, play and daytime 
sleepiness in patients with ASD. 5 studies found genetic abnormalities of melatonin receptor and enzymes involved in melatonin synthesis 
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Table 3. Cont. 
Review/meta-analysis 
Reading, 2012 
[104] 
ChildCare 
Health Dev. 
Correlation between plasmatic levels of melatonin and autistic behaviors was found. Melatonin groups showed improvements in total sleep duration and sleep onset latency versus placebo 
groups but not on night awakenings 
Letter to the editor 
Guénolé and 
Baleyte, 2011 
[105] 
Dev. Med. 
Child Neurol. 
Response to the Rossignol and Frye review [73]; Authors proposed that studies should explore separately sleep disorders in patients with ASD and sleep disorders in patients with Rett 
syndrome 
Guénolé and 
Baleyte, 2012 
[106] 
Pediatr. 
neurol. 
Response to the De Leersnyder et al. study [86] of open label trial. The definition of « chronic sleep disorder » did not refer to international classifications. Half of the children manifested 
Smith-Magenis syndrome that involves specific abnormalities of melatonin secretion. Thus, results can't apply to a population with ASD. The effects of melatonin should be studied separately 
in each neurodevelopmental disorder and with specific sleep diagnoses 
Discussion/Commentary  
Jan and 
Freeman, 2004 
[107] 
Dev. Med. 
Child Neurol. 
Discussion on melatonin use in children with ADHD, ASD, neurodevelopmental disabilities, epilepsy and blindness. Exogenous melatonin seems to regulate endogenous melatonin secretion. 
It seems to be more effective in sleep-wake cycle disorders with sleep onset delay disorders. Night and morning awakenings seem to be more difficult to treat, such as sleep problems associated 
with cerebral lesions. The more the child shows mental or motor comorbidities, the more the melatonin dose is high 
Lord, 1998 
[108]  
J Autism Dev. 
Disord 
General brief discussion of melatonin and its potential for treating sleep problems in autism 
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3. Treatment Studies of Melatonin in Autistic Spectrum Disorders 
A number of case studies and therapeutic trials of melatonin focused on individuals with 
developmental disorders and sleep problems have been reported. The main results of these studies, as 
well as relevant reviews and meta-analyses, are presented in Tables 2,3. 
Although potential therapeutic use of melatonin for sleep problems in autism have been considered 
for many years [108], available data in large samples of children with autistic disorder are very limited 
(see Table 2). Indeed, the studies have been hampered by small sample sizes of children with  
autism [81–84,86,87,89,94,96], or have been conducted on larger sample sizes of children with 
heterogeneous developmental disorders (children with autism mixed with blind children and/or children 
with multiple neurological disabilities associated with intellectual disability) with no indication with 
regard to the specificity of the results for the autism group [88,91,95–99]. As already indicated, there is 
an issue of potential non-specificity of the melatonin findings in ASD, especially given that melatonin is 
widely used as a treatment in other disorders associated with intellectual disability [96,109]. Further 
studies are required to test better the melatonin findings with regard to ASD or intellectual disability. An 
alternative hypothesis would be that the melatonin findings are related to impairments in certain 
dimensions, such as the communication or social domain, shared by several different disorders. Finally, 
it cannot be ruled out that the melatonin findings are related to sleep-wake rhythm disturbances without 
any specificity with regard to a particular disorder. However, it is noteworthy that in our studies [58,59], 
melatonin deficit was significantly associated with social communication impairments, but not with 
sleep problems. Future research on melatonin in ASD is required, including therapeutic trials, studying 
together melatonin levels, sleep problems, autistic behavioral impairments and cognitive level of 
functioning in order to better understand the relationships between these variables. 
Another major issue for clinical trials of melatonin in ASD is the loss of response to melatonin 
treatment underlined by Braam and colleagues for patients with intellectual disability and sleep 
problems, including patients with ASD [110,111]. In addition, Andersen et al. [85], in a retrospective 
study on 107 children with ASD that were prescribed melatonin for insomnia, found seven cases in 
which sleep initially improved, but sleep problems returned, despite dose escalation. Braam et al. [110,111] 
suggest that loss of response in these patients might be a result of exposure to persistent non-physiologic 
melatonin levels due to slow melatonin metabolism provoked by decreased activity of CYP1A2. In the 
case of loss of response, Braam et al. [110,111] recommend that melatonin dose should be greatly 
reduced, rather than increased. 
Furthermore, only a few of the therapeutic trials report results related to outcomes other than sleep, in 
particular autistic behavioral impairments. Thus, improvement of communication [97], social 
withdrawal [90,92], stereotyped behaviors and rigidity [92,94] or anxiety [90,95] was reported in 
children with ASD using melatonin. The relevant studies are detailed in Table 2. In addition, Jan and 
Freeman [107] discussed, based on their literature review of studies using dose escalation from 1–2 mg 
up to 15 mg, that the higher melatonin doses were reached in children with greater mental or motor 
comorbidities. It is noteworthy that several dose escalation studies were conducted (see Table 2), but 
there is currently no study of the dose-response relationship for melatonin in ASD. The strengths of the 
treatment studies mentioned above [90,92,94,95,97] are their interest for autistic behavioral impairments 
and their design which includes controlled trials of melatonin for all of them and randomized 
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double-blind, placebo-controlled trials for most of them [94,95,97]. However, some limitations can be 
noted. Thus, ASD populations studied [90,95,97] were often clinically heterogeneous (for example, 
autistic disorder according to DSM-IV-TR criteria can be mixed with pervasive developmental disorder 
not otherwise specified). The age range was very wide in some studies and prepubertal children  
were mixed with pubertal or postpubertal individuals [94,95,97]. This is a problem given that  
pineal melatonin secretion is influenced by age and pubertal stage [112,113]. In addition, autistic 
behavioral impairments were often not detailed enough (for example, Wright et al. [97] reported 
significant communication improvement but the results were not detailed with regard to verbal or 
non-verbal communication) or were not always assessed using validated tools (for example, Garstang 
and Wallis [94] reported decreased rigidity based only on parents’ and teachers’ comments and  
Wasdell et al. [95] reported decreased anxiety based on caregivers’ comments). Finally, it is noteworthy 
that no clinical trial of melatonin in autistic disorder used behavioral autistic impairments as their main 
outcome criteria. Further therapeutic trials of melatonin are necessary, conducted on large samples of 
prepubertal children with autistic disorder and using validated behavioral assessments, to study better 
the evolution of autistic behavioral impairments following administration of melatonin. 
4. Relationships between Melatonin and Autistic Behavioral Impairments 
The relationships between melatonin and autistic behavioral impairments are discussed below with 
regard to the three main DSM-IV-TR domains of autism (communication including verbal/non-verbal 
communication, reciprocal social interactions, and restricted, repetitive and stereotyped behaviors or 
interests with difficulties adapting to change) and the role of synchrony of rhythms in social 
communication development. 
4.1. Melatonin and Communication 
4.1.1. Melatonin and Autistic Communication Impairments 
As seen in the previous section, some studies suggest that administration of melatonin to individuals 
with autistic disorder improves their communication deficit [97]. Furthermore, we found that nocturnal 
excretion of 6-sulphatoxymelatonin (6-SM) was significantly negatively correlated with severity in the 
overall level of verbal language [59]. This observation of significant negative correlations between 
nocturnal 6-SM excretion and severity of autistic impairment in verbal communication replicates our 
previous finding [58]. It is noteworthy that we replicated this result using the ADI-R (the ADI-R is based 
on a parental interview) which differs from the ADOS (the Autism Diagnostic Observation Schedule is 
based on a direct observation of the patient [114]) used in our previous study. The significant positive 
correlation between verbal IQ scores and nocturnal 6-SM excretion found in the Tordjman et al.  
study [58] goes in the same direction, although the range of IQ scores in the patients was too narrow to 
thoroughly test the relationship between IQ scores and 6-SM levels. The observed correlations between 
severity of communication impairments and decreased nocturnal 6-SM excretion might be related to 
previous reports of an association between communication impairments and problems with sleep onset 
in low-functioning children [115]. Thus, some authors suggest that problems of sleep initiation and 
maintenance in children with ASD may alter their cognitive development, including memory, learning 
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and communication [116]. Other authors suggest that language performance displays an internally 
generated circadian rhythmicity following the sleep-wake rhythm (the optimal time for parsing language 
would occur between 3 to 6 h after the habitual wake time) [117]. However, the results obtained in our 
first study [58] did not indicate that melatonin excretion was closely associated with degree of sleep 
disturbance in children with autism and using a brief sleep assessment we did not observe sleep 
problems in the post-pubertal subjects of our second study [59]. It is noteworthy that melatonin has been 
reported to affect the temporal organization of the song of the Zebra Finch [118]. However, it should  
also be noted that the circadian pattern of song production was not altered, suggesting that melatonin 
might be able to influence social behavior through non-circadian pathways. In addition, Nir and 
colleagues [65] presented data suggestive of reduced melatonin production in individuals with autism 
and speech difficulties or with EEG abnormalities. More compelling is the agreement between our 
finding of a negative relationship of nocturnal 6-SM excretion with severity of language impairment and 
the study by Hu and colleagues [119] in ASD that reported substantially reduced expression of the gene 
encoding arylalkylamine N-acetyltransferase (AA-NAT, the rate limiting enzyme for melatonin 
synthesis) in ASD individuals with severe language impairment. Finally, the lower mean melatonin 
production, the significantly smaller day-night differences and the significantly higher frequency of 
absence of circadian variation observed in individuals with autism compared to controls, might be 
playing a role in, or be a reflection of, the hypothesized timing problems in “biological clocks” in  
autism [120,121]. Indeed, melatonin signals can drive daily rhythmicity and are also involved in the 
synchronization of peripheral oscillators [26]. Thus, Boucher suggests that timing problems in 
“biological clocks” would have physiological and psychological consequences that might be involved in 
autistic impairments. Wimpory et al. [121] have theorized that anomalies in clock genes operating as 
timing genes in high frequency oscillator systems may underline timing deficits that could be important 
in the development of autistic disorder, notably in autistic communication impairment.  
4.1.2. Role of Synchrony of Rhythms in Communication Development 
The role of melatonin on daily rhythmicity and synchronization of rhythms suggests that melatonin 
might be involved in motor and emotional synchrony. In line with the hypothesis of ergodicity [122]  
that postulates the existence of similar mechanisms at different levels, relationships might exist  
between cellular communication networks involving a cellular synchrony (synchronization of cellular 
oscillations) and early communication development involving a synchrony of motor and emotional 
rhythms. This provides a new perspective for considering the relationships between melatonin and 
communication. Abnormal melatonin production might impair the development of communication as 
well as socialization (see next section), two main domains of autistic disorder. It is noteworthy that 
congenitally blind children with consequently abnormal melatonin secretion and synchronization, very 
frequently meet criteria for autistic disorder (up to 42% [123]), whereas hearing impaired children, 
including hearing loss, meet criteria less frequently (up to 10% [124]). 
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4.2. Melatonin and Social Interaction  
4.2.1. Melatonin and Autistic Social Interaction Impairments 
Administration of melatonin was reported in two studies [90,92] to improve social withdrawal in 
children with ASD. In addition, nocturnal excretion of 6-SM was significantly correlated with severity 
of autistic social interaction impairments, in particular with imitative social play assessed in a study 
using the ADI-R [59] and with play assessed in another study using the ADOS [58]. These results, taken 
together with the importance of synchrony of rhythms in the development of social imitation and very 
early social interaction, suggest a possible role of melatonin in autistic social interaction impairments. 
4.2.2. Role of Synchrony of Rhythms in Social Interaction Development 
Concerning the development of social interaction, it is important to highlight the major role of 
synchrony of rhythms in bonding. Thus, Guedeney et al. [125] emphasize the importance of 
synchronization between infant and parental rhythms in very early social interaction and 
socio-emotional development, from biological rhythms during pregnancy to later exchange between 
caregiver and child.  
Human learning and cultural evolution are supported by paradoxical biological adaptation. We are 
born immature; yet, immaturity has value: “Delaying maturation of cerebral cortex allows initial 
learning to influence the neural architecture in ways that support later, more complex learning” [126]. 
Early learning appears to be computational [127] and to be based on perceptual-action mapping [126]. 
Learning is also social [128] and supported by skills present in infancy: imitation, shared attention and 
empathic understanding [126]. The whole social system which contributes to interactional synchrony 
may be disrupted in infant who will subsequently develop autism. It is likely that an atypical social 
trajectory in the infant would affect parents’ interactive patterns. Temporally, the interactive nature of 
human social relationships implies that a message ai produced by A impacts B who, in return, produces 
message bi and so on, indicating that some form of reciprocity occurs between partners A and B [129]. 
Synchrony is difficult to define and delimit. Numerous terms have been used to describe the 
interdependence of dyadic partners’ behaviors (mimicry, social resonance, coordination, synchrony, 
chameleon effect, etc.). Here, we define synchrony as the dynamic and reciprocal adaptation of the 
temporal structure of behaviors between interactive partners [130]. In typically developing children, the 
quality of social interaction depends on an active dialogue between the parent and the infant based on the 
infant’s desire to be social and the parent’s capacity to be attuned [131,132]. Numerous studies have 
emphasized the importance of synchrony and co-modality [133]. Also, synchrony between partners has 
been correlated with biological markers. Dumas et al. [134] use hyper-scanning recordings to examine 
brain activity, including measures of neural synchronization between distant brain regions of interacting 
individuals through a free exchange of roles between the imitator and the model. Their study was the 
first to record dual EEG activity in dyads of subjects during spontaneous nonverbal interaction. Five 
female-female pairs and 6 male-male pairs were scanned. They showed that interpersonal rhythmic 
oscillations were correlated with the emergence of synchronization in the brain’s alpha-mu band (an area 
involved in social interaction [135]) between the right centro-parietal regions. Correlation at biological 
levels has also been found. Naturally occurring variations in maternal behavior are associated with 
Int. J. Mol. Sci. 2013, 14 20528 
 
 
differences in estrogen-inducible central oxytocin receptors, which are involved in pro-social  
behaviors [136]. Oxytocin appears to enhance both maternal/paternal as well as affiliative behaviors in 
humans and is considered as the bonding hormone [137].  
These developments have prompted developmental psychologists to study early interaction not only 
as the addition of two behaviors but rather as a single phenomenon with a dialogue between two partners 
engaged in behavioral and emotional exchange. Rhythm, synchrony and emotion are increasingly being 
viewed by developmental psychologists as key aspects of appropriate early interaction [133].  
Very few studies have addressed the importance of infant-caregiver synchrony/reciprocity in  
early interactions involving infants who will subsequently develop autism. Studies using early home 
videos [138,139] parental interviews [140] and prospective assessment of siblings of children with  
ASD [141,142] have revealed atypical developmental tendencies in infants who were later diagnosed 
with ASD. The first signs are abnormalities with eye contact, imitation, disengagement, joint  
attention, orienting to name, and body language. These behaviors constitute important precursors of 
later-developing symptoms. However, whether these first signs impact the interactive process between 
an infant and their parents and whether they influence the development of the infant himself remain two 
complex and unexplored issues. In two related studies based on home movies, Saint-Georges et al. [138] 
and Cohen et al. [143] showed that when studying interactive patterns in infants with computational 
methods to take into account motor and emotional synchrony between partners: (i) deviant autistic 
behaviors appeared before 12 months; (ii) parents felt weaker interactive responsiveness and mainly 
weaker initiative from their infants; (iii) parents tried increasingly to supply soliciting behaviors through 
touching; fathers’ involvement in interacting with infants that will develop autism significantly 
increased after 12 months compared to typical developing infants. It is likely that these modifications of 
interactive patterns implicate numerous co-influences due to the reciprocal nature of these processes. 
In fact, it is difficult to separate social from communication development given that emotional 
synchrony, as well as imitation, play a role in both domains. It might be more appropriate, at this point, 
to consider the combined domain of social communication as does the most recent version of the scale 
ADOS [114], as well as the recently released DSM-V. Thus, many studies have referred to the 
difficulties observed in children with autism in imitating other people’s faces, gestures or vocal signals 
to better understand their problems with social interaction and speech development. This specific type of 
imitation is referred to as “spatial” imitation to highlight the capacity to produce an instantaneous copy 
of the form of the signal. However, another way to communicate and interact with others is to perform a 
“temporal” imitation of their behavior [144]. This is what humans do when singing, dancing, foot 
tapping or drumming in synchrony with others. The uniqueness of temporal imitation is that there is no 
need to use the same motor pattern to succeed in communicating and interacting: the synchronization 
can occur in movements as simple as finger tapping in synchrony with another person’s body swaying, 
foot tapping in response to complex songs, or even eye blinking. While both animals and humans are 
able to perceive rhythms and produce rhythmic motor patterns, the capacity to adapt the rhythm of their 
movements to an external auditory or visual rhythm is unique to humans [145] (except in the cockatoo, a 
non-human vocal learning species [146]). Being rhythmically synchronized with his/her environment is 
crucial for an infant’s emotional, cognitive, social and sensorimotor development [147,148]. 
Developmental studies have shown that the ability to perceive, as seen previously, and produce rhythms 
is already present in the human fetus and newborn [149], Barburoth et al., in preparation. However, the 
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capacity to produce temporally-adapted motor patterns emerges later, depending on the motor system 
used (sucking, finger or hand movement) and the difference between the beat and the spontaneous motor 
tempo of the infant’s movement [150,151]. Further research is requested to explore the development of 
children with autism with regard to their capacity to adapt their own rhythm to an external rhythm. 
Previous studies suggest disorganized rhythms are associated with stereotypies and poor synchrony in 
these children [152]. Given this background, it is remarkable that melatonin levels have been reported to 
be low in individuals with autism and negatively correlated with the severity of verbal communication 
and social imitative play impairments. It could be hypothesized that melatonin, as a regulator of 
biological rhythms, could enhance the capacity of children with ASD to produce motor-temporal 
imitation. In this case, administration of melatonin could help them to synchronize their movements with 
movements of others (playing situations) and with external rhythmic auditory stimuli, such as music 
and/or the human voice (enhancing their verbal skills). Furthermore, administration of melatonin may 
change the spontaneous motor tempo of treated children’s movements and enlarge the scope of 
adaptability of these movements to external stimuli. A third hypothesis is that melatonin treatment may 
increase the perception of rhythms in children with autism. All of these hypotheses need to be tested and 
open new avenues for exciting research in the field of synchronization and social communication  
in ASD.  
4.3. Melatonin and Restricted, Repetitive and Stereotyped Behaviors or Interests 
4.3.1. Melatonin and Stereotyped Behaviors  
Repetitive behaviors can be speculated to be an attempt to produce repeated sequences in order to 
compensate for a lack of daily rhythmicity and synchronized rhythms due to the low melatonin 
production in ASD. Our finding [59] observed in a sample of 43 adolescents and young adults with 
autistic disorder (nocturnal excretion of 6-SM was significantly negatively correlated with repetitive use 
of objects) taken together with the improvement of stereotyped behaviors reported following administration 
of melatonin in 24 children and adolescents with ASD [92] lend some support to this hypothesis. 
Donald Winnicott [153] emphasized that “the main problem for a typically developing child is to be 
able to create a continuum out of discontinuity”. According to him, the first optimal container (“holding 
environment”) for the newborn is the progressive internalization of the rhythmic structures of feeding 
(rhythmic ebb and flow corresponding to the kinesthetic experience of suckling), providing a sense of 
continuing existence. We can nevertheless hypothesize that this internalization process starts far earlier, 
in the womb. It is through the regular repetition of identical sequences of discontinuity, such as the 
circadian rhythms that are already present during the fetus life, that a continuum is constructed, together 
with the sense of continuing existence. Conversely, based on clinical observations in autism, we could 
say that children with autism create discontinuity out of continuity. Many of these children need to create 
discontinuity that is repeated at regular intervals, which could have been fundamentally lacking in their 
physiological development. This overriding need can be observed when children with autism are 
exposed to stress. It may also occur when they are confronted with a representation of continuity 
(drawing of a circle, prolonged wait with inactivity, etc.). It is at these times that we often witness the 
emergence of behavioral stereotypies, consisting of body oscillations, repetitive utterances or, for those 
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with graphic skills, the compulsion to write out sequences of numbers. These compulsions might arise 
from obsessive mechanisms involving a need for control and perhaps, above all, an existential need to 
produce discontinuous but equidistant patterns. Sylvie Tordjman [154] reported the case of a 
high-functioning adult with autism, a patient of René Diatkine (filmed sessions providing an extremely 
interesting and scientifically significant account [155]), who complained of being assailed by a constant 
flow of thoughts and was only able to overcome his anxiety by ending all his sentences with a pause. 
When he was a child, this same patient could not stand circles and spent his time producing geometric 
figures made up of broken lines. The irregular, if not arrhythmic, circadian rhythms reported in some 
individuals with autism suggest that the development of children with autism is based not on regularly 
repeated physiological discontinuities, but on anarchic discontinuities and even, in many cases, on an 
“endless” physiological continuity provoked by the absence of variation in melatonin levels.  
Oscillatory, pendular or vortical rhythmic structures appear to be the form, expression and 
representation of the life instinct and life drive in their most biological essence [156]. Identical patterns, 
through a stable rhythm repeated at regular intervals, allow us to face up to anxiety about definitive loss 
and disappearance, and therefore to face up to fears of death. Conversely, it is when this internal rhythm 
is absent that we witness the emergence of motor stereotypies and ruminations in individuals with 
autism, as indicated by our results [59]. We can state the hypothesis that children with autism, 
confronted with this “endless” physiological continuity (or, at the very least, with this absence of 
physiological discontinuities repeated at regular intervals), develop disorganizing existential anxieties 
and therefore they try to control them through stereotyped behaviors. Thus, they may become 
completely absorbed in unimodal stereotyped behaviors involving the overloading of a sensory channel 
(auditory, visual, kinesthetic, tactile, etc.) that enables them to be totally centered on the present 
moment. As a result, these children are locked into the present moment, entirely focused on their sensory 
self-stimulations, and this raises the question of their representations of the past or future [154]. 
4.3.2. Melatonin and Adaptation to Change 
Abnormally low daytime and nighttime melatonin secretion was associated with an absence of 
melatonin circadian variation in individuals with autism [59,66,77], which in turn, given the 
synchronizer role of melatonin, also has consequences for the circadian rhythms network This blunted 
circadian rhythmicity with no or little variability might be related to the difficulties in adapting to 
changes associated with repetitive and restricted interests typically observed in individuals with autism. 
Thus, we can hypothesize that children with autism who are confronted with physiological continuity 
due to absent circadian rhythms have difficulties to adapt to changes in either their external or their 
internal environment. In which case we should talk about intolerance to change, rather than a need for 
changelessness, or the “preservation of sameness” described by Leo Kanner [157]. For, as we saw 
earlier, continuity (“the endless continuum”) is as stressful as unpredictable disruptions. This underlines 
the importance of the circadian rhythms network synchronized by melatonin and involving an internal 
system of continuity/discontinuity that may participate to the developmental process of adaptation to 
environmental changes. 
This difficulty in children with autism to adapt to change is also observed with regard to changes in 
the rhythm of environmental stimuli. Sometimes, this difficulty may even spark off an epileptic seizure 
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(epilepsy is observed in nearly a third of children with autism [158]), due to the unusually rapid rhythm 
of a sensory stimulus, such as the pulsing light of a stroboscope. The latter can disturb the rhythmic 
activity of a particular brain area, leading it to fall out of sync with the rest of the brain and causing its 
population of neurons to fire (depolarization). It is noteworthy that individuals with autism and seizures 
tended to have an abnormal rhythm of melatonin correlated with EEG changes [65]. Patients with autism 
are particularly sensitive not only to changes in the rhythm of the external environment but also to ones 
occurring in their internal environment. Thus, some female adolescents with autism experience epileptic 
seizures towards the 14th day of their menstrual cycle, which is when luteinizing hormone (LH) levels 
peak. We end up with a chain of events where a change in rhythm associated with excessive 
environmental stimuli would strongly increase arousal and provoke physiological stress which would in 
turn, for some children with autism, lead to an epileptic seizure. This underscores the importance for 
individuals with autistic disorder of maintaining stable physiological rhythms. 
5. Conclusions 
The importance of rhythms can be applied to the calming and relaxing effect of visual and auditory 
stimuli featuring repeated movements with a stable rhythm, such as the ebb and flow of waves or the 
regular ticking of a clock… This beneficial effect opens interesting perspectives and was known about 
long ago in the treatment of mental illness. Thus, the former psychiatric hospital in the Syrian city of 
Aleppo had “treatment fountains” where the rhythm of the water flow varied according to the pathology 
(depression, schizophrenia, etc.) [159]. André Bullinger [160] is using sensory (tactile, auditory, visual, 
olfactory and vestibular) flows to treat children with autistic disorder, based on compensation 
techniques. The objective is to create a substitute flow made up of stable sequences of sensory stimuli 
that are regularly repeated, in order to allow children to extract invariants from a system of 
continuity-discontinuity. New therapeutic perspectives for autistic disorder could be developed in order 
to create continuity from sensory discontinuities regularly repeated with a stable rhythm, and possible 
moments of emotional synchrony. Thus, it appears important to introduce relational variants with 
emotional synchrony into a background of invariants, repeated at stable and regular intervals, making up 
the “holding” environment of continuity. This probably accounts for the therapeutic effectiveness of 
Bullinger’s technique [159], whereby a checkerboard is moved rhythmically in front of a child with 
autism in order to set up substitute optical flows. At the same time, the therapist looks directly at the 
child and attempts to share moments of emotional and relational synchrony.  
To develop therapeutic new perspectives in ASD, first it is necessary to restore some basic regular 
physiological rhythms such as circadian rhythms. Thus, prescribing small physiologic doses of 
melatonin could help to restore the impaired circadian melatonin rhythm in ASD which disturbs the 
sleep-wake rhythm, but more generally the synchronization of internal biological clocks, resulting in the 
absence of homogeneous and harmonious rhythmicity with the consequences previously described on 
social communication, stereotyped behaviors and adaptation to environmental changes. It may well be 
this internal asynchrony that causes children with autism to feel permanently “out of sync” with other 
people. We can refer here again to René Diatkine’s patient—a high-functioning adult with autism—who 
explained during a filmed session that he is never in sync with others despite his efforts to  
adjust [155]. Randomized clinical trials in ASD are warranted to establish potential therapeutic efficacy 
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of melatonin for social communication impairments and stereotyped behaviors or interests. In particular, 
studies of the dose-response relationship for melatonin in ASD are necessary in complement of dose 
escalation studies. We are currently conducting a therapeutic trial studying melatonin dose-effect 
relation in 32 male children with autistic disorder (Clinical Trials.Gov.: NCT01780883, ANSM 
A91245-56 [161]); the main objective of this randomized, double-blinded, placebo-controlled trial is to 
assess the melatonin effect on the severity of behavioral autistic impairments. Furthermore, future trials 
should aim at determining optimal clinical responses by the association of light treatment with 
melatonin. Thus, therapeutic effects might be in part mediated by enhancement of the circadian system 
functioning. This supports inclusion of chronotherapeutic strategies in the treatment options offered to 
individuals with ASD. 
Finally, it might be interesting to take into account physiological rhythms, such as sleep-wake and 
eating rhythms, for the care provided to individuals with ASD (prescription of regular set times for 
eating and sleeping) and for the patient follow-up. Indeed, these physiological rhythms, in particular 
sleep-wake rhythms, can give important clues to look for positive trends in the follow-up. 
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